Abvc Biopharma (ABVC) Times Interest Earned (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Times Interest Earned came in at 18.42 in Q2 2026, down 3.86% on a YoY basis from 19.16 in Q2 2025, and up 42.16% quarter-over-quarter from 31.85 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Times Interest Earned (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Times Interest Earned for 14 consecutive years, with 18.42 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Times Interest Earned fell 3.86% year-over-year to 18.42; the trailing twelve-month figure through Jun 2026 stood at 41.98 (down 729.61% YoY), and the FY2025 full-year result was 17.2, down 201.82% from the prior year.
- Times Interest Earned rose to 18.42 in Q2 2026 per ABVC's latest filing, from 31.85 in the prior quarter.
- Across five years, Times Interest Earned topped out at 6.7 in Q4 2023 and bottomed at 341.44 in Q1 2022.
- Historically, Times Interest Earned has averaged 44.84 across 5 years, with a median of 18.77 in 2026.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned soared 128.76% in 2023, then tumbled 4526.38% in 2025.
- Over 5 years, Times Interest Earned stood at 23.3 in 2022, then jumped by 128.76% to 6.7 in 2023, then sank by 148.51% to 3.25 in 2024, then sank by 1977.84% to 67.55 in 2025, then soared by 72.73% to 18.42 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered 18.42, 31.85, and 67.55 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -18.42 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.42 |
| Mar 31, 2026 | -31.85 |
| Dec 31, 2025 | -67.55 |
| Sep 30, 2025 | -63.45 |
| Jun 30, 2025 | -17.73 |
| Mar 31, 2025 | -3.11 |
| Dec 31, 2024 | -3.25 |
| Sep 30, 2024 | -1.37 |
| Jun 30, 2024 | -4.15 |
| Mar 31, 2024 | -15.62 |
| Dec 31, 2023 | 6.70 |
| Sep 30, 2023 | -1.77 |
| Jun 30, 2023 | -19.12 |
| Mar 31, 2023 | -33.64 |
| Dec 31, 2022 | -23.30 |
| Sep 30, 2022 | -29.37 |
| Jun 30, 2022 | -138.69 |
| Mar 31, 2022 | -341.44 |
| Dec 31, 2021 | 264.59 |
| Sep 30, 2021 | -50.95 |